Evidence map›Paper›PMID 28754693›Full record

ArticleThe Journal of biological chemistry2017

Funiculosin variants and phosphorylated derivatives promote innate immune responses via the Toll-like receptor 4/myeloid differentiation factor-2 complex.

Naoki Okamoto, Keisuke Mizote, Hiroe Honda, Akinori Saeki, Yasuharu Watanabe, Tomomi Yamaguchi-Miyamoto, Ryutaro Fukui, Natsuko Tanimura, Yuji Motoi, Sachiko Akashi-Takamura and 11 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 2 countries.

Naoki OkamotoFrom the Department of Immunobiology and Pharmacological Genetics, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194.
Keisuke Mizotethe Laboratory of Natural Product Chemistry, Department of Chemistry, School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043.
Hiroe HondaFrom the Department of Immunobiology and Pharmacological Genetics, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194.
Akinori Saekithe Laboratory of Natural Product Chemistry, Department of Chemistry, School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043.
Yasuharu WatanabeFrom the Department of Immunobiology and Pharmacological Genetics, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194.
Tomomi Yamaguchi-Miyamotothe Toyama Prefectural Institute for Pharmaceutical Research, 17-1 Nakataikouyama, Imizu City, Toyama 939-0363.
Ryutaro Fukuithe Division of Innate Immunity, Department of Microbiology and Immunology.
Natsuko Tanimurathe Division of Innate Immunity, Department of Microbiology and Immunology.
Yuji Motoithe Division of Innate Immunity, Department of Microbiology and Immunology.
Sachiko Akashi-Takamurathe Department of Microbiology and Immunology, School of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195.
Tatsuhisa Katothe Teika Pharmaceutical Co., Ltd., 1-3-27 Arakawa, Toyama-shi, Toyama 930-0982.
Shigeto Fujishitathe Teika Pharmaceutical Co., Ltd., 1-3-27 Arakawa, Toyama-shi, Toyama 930-0982.
Takahito Kimurathe Teika Pharmaceutical Co., Ltd., 1-3-27 Arakawa, Toyama-shi, Toyama 930-0982.
Umeharu Ohtothe Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033.
Toshiyuki Shimizuthe Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033.
Takatsugu Hirokawathe Molecular Profiling Research Center for Drug Discovery, AIST, 2-3-26 Aomi, Koto-ku, Tokyo 135-0064.
Kensuke Miyakethe Division of Innate Immunity, Department of Microbiology and Immunology.
Koichi Fukasethe Laboratory of Natural Product Chemistry, Department of Chemistry, School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043.
Yukari Fujimotothe Japan Science and Technology Agency (JST), PRESTO, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan.
Yoshinori NagaiFrom the Department of Immunobiology and Pharmacological Genetics, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, ynagai@med.u-toyama.ac.jp.
Kiyoshi TakatsuFrom the Department of Immunobiology and Pharmacological Genetics, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, takatsuk@med.u-toyama.ac.jp.
Innate Pharma (France) · FROsaka University · JPToyama Prefectural Institute for Pharmaceutical Research · JPUniversity of Toyama · JPThe University of Tokyo · JPAichi Medical University · JPKeio University · JPTokyo University of Science · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Toll-like receptor 4 (TLR4)/myeloid differentiation factor-2 (MD-2) complex is essential for LPS recognition and induces innate immune responses against Gram-negative bacteria. As activation of TLR4/MD-2 is also critical for the induction of adaptive immune responses, TLR4/MD-2 agonists have been developed as vaccine adjuvants, but their efficacy has not yet been ascertained. Here, we demonstrate that a funiculosin (FNC) variant, FNC-RED, and FNC-RED and FNC derivatives are agonists for both murine and human TLR4/MD-2. FNC-RED induced nuclear factor-κB (NF-κB) activation via murine TLR4/MD-2, whereas FNC had no TLR4/MD-2 stimulatory activity. Biacore analysis revealed that FNC-RED binds to murine TLR4/MD-2 but not murine radioprotective 105 (RP105)/myeloid differentiation factor-1 (MD-1), another LPS sensor. FNC-RED induced CD14-independent expressions of pro-inflammatory cytokines and co-stimulatory molecules in murine macrophages and dendritic cells. In contrast, FNC-RED stimulation was reduced in CD14-dependent LPS responses, including dimerization and internalization of TLR4/MD-2 and IFN-β expression. FNC-RED-induced IL-12p40 production from murine dendritic cells was dependent on NF-κB but not MAPK pathway. In addition, fetal bovine serum augmented lipid A-induced NF-κB activation but blocked FNC-RED-mediated responses. Two synthetic phosphate group-containing FNC-RED and FNC derivatives, FNC-RED-P01 and FNC-P01, respectively, activated human TLR4/MD-2, unlike FNC-RED. Finally, computational analysis revealed that this species-specific activation by FNC-RED and FNC-RED-P01 resulted from differences in electrostatic surface potentials between murine and human TLR4/MD-2. We conclude that FNC-RED and its synthetic derivative represent a novel category of murine and human TLR4/MD-2 agonist.

Indexed as

Models, ImmunologicalAnimalsBinding SitesBone Marrow CellsCell LineCells, CulturedComputational BiologyDendritic CellsDrug DesignHumansImmunity, InnateLigandsLymphocyte Antigen 96MacrophagesMice, Inbred C57BLMice, Knockoutfuniculosin (pyridone)LigandsLY96 protein, humanLymphocyte Antigen 96PyridonesRecombinant Fusion ProteinsTLR4 protein, humanToll-Like Receptor 4adjuvantdendritic cellinnate immunitymacrophageNF-κB (NF-KB)TLR4/MD-2toll-like receptor (TLR)

Identifiers

PMID28754693
PMCPMC5602397
OpenAlexW2740873553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.